419 related articles for article (PubMed ID: 33741296)
1. Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study.
Joshi M; Holder SL; Zhu J; Zheng H; Komanduri S; Warrick J; Yasin H; Garje R; Jia B; Drabick JJ; DeGraff DJ; Zakharia Y
Eur Urol Focus; 2022 Mar; 8(2):483-490. PubMed ID: 33741296
[TBL] [Abstract][Full Text] [Related]
2. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
3. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
4. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
7. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
Galffy G; Lugowska I; Poddubskaya EV; Cho BC; Ahn MJ; Han JY; Su WC; Hauke RJ; Dyar SH; Lee DH; Serwatowski P; Estelles DL; Holden VR; Kim YJ; Vladimirov V; Horvath Z; Ghose A; Goldman A; di Pietro A; Wang J; Murphy DA; Alhadab A; Laskov M
ESMO Open; 2023 Jun; 8(3):101173. PubMed ID: 37141847
[TBL] [Abstract][Full Text] [Related]
8. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
[TBL] [Abstract][Full Text] [Related]
9. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Hoffman-Censits J; Grivas P; Powles T; Hawley J; Tyroller K; Seeberger S; Guenther S; Jacob N; Mehr KT; Hahn NM
Future Oncol; 2024 Feb; 20(4):179-190. PubMed ID: 37671748
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Koczywas M; Frankel PH; Synold TW; Lenz HJ; Mortimer JE; El-Khoueiry AB; Gandara DR; Cristea MC; Chung VM; Lim D; Reckamp KL; Lau DH; Doyle LA; Ruel C; Carroll MI; Newman EM
Br J Cancer; 2014 Dec; 111(12):2268-74. PubMed ID: 25349975
[TBL] [Abstract][Full Text] [Related]
13. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Iacovelli R; Ciccarese C; Brunelli M; Battelli N; Buttigliero C; Caserta C; Buti S; Santini D; Carella C; Galli L; Verri E; Ermacora P; Merler S; Masini C; De Vivo R; Milesi L; Spina F; Rizzo M; Sperduti I; Fornarini G; Tortora G
Ann Oncol; 2022 Nov; 33(11):1179-1185. PubMed ID: 35926813
[TBL] [Abstract][Full Text] [Related]
14. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
Strauss J; Deville JL; Sznol M; Ravaud A; Maruzzo M; Pachynski RK; Gourdin TS; Maio M; Dirix L; Schlom J; Donahue RN; Tsai YT; Wang X; Vugmeyster Y; Beier F; Seebeck J; Schroeder A; Chennoufi S; Gulley JL
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37236636
[TBL] [Abstract][Full Text] [Related]
15. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
16. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Hurwitz ME; Tannir NM
Eur Urol; 2022 Oct; 82(4):365-373. PubMed ID: 35643589
[TBL] [Abstract][Full Text] [Related]
17. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
[TBL] [Abstract][Full Text] [Related]
18. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
[TBL] [Abstract][Full Text] [Related]
19. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
Li H; Sahu KK; Brundage J; Benson M; Swami U; Boucher KM; Gupta S; Hawks J; Sirohi D; Agarwal N; Maughan BL
Oncologist; 2023 Aug; 28(8):737-e693. PubMed ID: 36952231
[TBL] [Abstract][Full Text] [Related]
20. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
